Technical Data Sheet

Purified NA/LE Mouse Anti-Human IFN-α[2b]

Product	Inform	ation
---------	--------	-------

Material Number:	551795
Alternate Name:	IFNa, IFNα
Size:	0.5 mg
Concentration:	1.0 mg/ml
Clone:	7N4-1
Immunogen:	Human IFN-α2b
Isotype:	Mouse IgG1, ĸ
Reactivity:	QC Testing: Human
Storage Buffer:	No azide/low endotoxin: Aqueous buffered solution containing no preservative,
	0.2µm sterile filtered. Endotoxin level is $\leq 0.01 \text{ EU/µg}$ ($\leq 0.001 \text{ ng/µg}$) of
	protein as determined by the LAL assay.

Description

The 7N4-1 antibody reacts with human IFN- α 2b and to a lesser extent with IFN- α 7. It does not react with IFN- α 1 nor IFN- α 4. IFN- α 2b is one of the three variants of IFN- α 2 that have been isolated from human cell lines. IFN- α 2b is the variant predominantly produced by human leukocytes. Human IFN-a2b belongs to the IFN-a class of proteins also known as leukocyte interferons. IFN-a comprises a family of related but distinct proteins with molecular weights ranging from 16-27 kDa with antiviral, antiproliferative and immunomodulatory activities. The IFN-a family is composed from as many as 14 different genes. The immunogen used to generate the 7N4-1 hybridoma was E. coli-expressed recombinant human IFN-α2b. This is a neutralizing antibody.

Preparation and Storage

Store undiluted at 4°C.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Application Notes

Application

Intracellular staining (flow cytometry)	Routinely Tested
Neutralization	Tested During Development
Immunocytochemistry (cytospins)	Reported

Neutralization Activity:

This antibody has been reported to be useful for the neutralization of recombinant human IFN-a. Neutralization activity may be measured using MTT dye conversion in a IFN-a mediated EMC viral resistance assay using A549 as indicator cells.

50% Neutralization (ND50) at 0.3 - 3 µg/mL

 $\geq 95\%$ Neutralization at 10 - 50 $\mu\text{g/mL}$

Suggested Companion Products

talog Number	Name	Size	Clone
721	Purified NA/LE Mouse IgG1 k Isotype Control	0.5 mg	107.3

Product Notices

Since applications vary, each investigator should titrate the reagent to obtain optimal results. 1.

Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols. 2.

References

Ca

554

Dipaola M, Smith T, Ferencz-Biro K, Liao MJ, Testa D.. Interferon-alpha 2 produced by normal human leukocytes is predominantly interferon-alpha 2b. J Interferon Res. 1994: 14(6):325-332. (Biology)

Green JA, Yeh TJ, Overall JC. Rapid, quantitative, semiautomated assay for virus-induced and immune human interferons. J Clin Microbiol. 1980; 12(3):433-438. (Methodology: Neutralization)

Lydon NB, Favre C, Boye S, et al. Immunochemical mapping of alpha-2 interferon. Biochemistry, 1985; 24(15);4131-4141, (Immunogen)

Pestka S. The human interferons—from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond. Arch Biochem

Biophys. 1983; 221(1):1-37. (Biology)

Pestka S. The human interferon alpha species and receptors. 2000; 55(4):254-287. (Biology)

Pestka S. Interferon from 1981 to 1986. Methods Enzymol. 1986; 119:3-14. (Biology)

Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999; 284(5421):1835-1837. (Clone-specific: Immunocytochemistry (cytospins))

Vogel S, Friedman R, Hogan M. Measurement of antiviral activity induced by interferons a, b, and g.. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, ed. Current Protocols in Immunology. New York: John Wiley & Sons; 2007:6.9.1-6.9.15. (Methodology: Neutralization)

BD Biosciences

DL	•	DI	U	5	u	e	 Ce

bdbiosciences.	com					
United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean	
877.232.8995	800.979.9408	32.53.720.550	0120.8555.90	65.6861.0633	55.11.5185.9995	
For country co	ntact informatio	on, visit bdbiosci	ences.com/conta	ict		
Conditions: The in	nformation disclose	d herein is not to b	e constructed as a n	ecommendation to u	use the above product in violation	
of any patents. Bl	D Biosciences will n	ot be help responsi	ble for patent infrin	gement or other vio	lations that may occur with the	
use of our produc	ts. Purchase does n	ot include or carry	any right to resell o	r transfer this produ	ct either as a stand-alone	
product or as a co	moonent of anoth	er product. Any use	of this product oth	er than the nermitte	nd use without the express	



product other than the permitted use without the express written authorization of Becton, Dickinson and Company is stictly prohibited. For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale. Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2011 BD